Table A1.
Univariate Cox regression analysis.
| Factor | PFS | OS | ||
|---|---|---|---|---|
| HR (95%CI) | p | HR (95%CI) | p | |
| Age (<65 vs. ≥65 years) | 1.36 (0.6–2.7) | 0.38 | 2 (0.93–4.4) | 0.07 |
| Sex (male vs. female) | 2.62 (0.8–8.7) | 0.11 | 3.2 (0.7–13.6) | 0.11 |
| ECOG PS (≤1 vs. 2) | 1.9 (0.94–3.9) | 0.07 | 2.4 (1.1–5.2) | 0.022 * |
| Histology (adeno. vs. squamous) | 0.7 (0.36–1.7) | 0.55 | 0.8 (0.34–1.9) | 0.62 |
| Stage (IIIB vs. IV) | 2.5 (0.7–8.3) | 0.13 | 4 (0.9–17.4) | 0.057 |
| N° mets. (≤1 vs. ≥2) | 1.4 (0.7–2.9) | 0.29 | 1.58 (0.7–3.3) | 0.22 |
| Bone mets. (no vs.yes) | 2.4 (1.1–5.3) | 0.038 * | 2.6 (1.1–6.1) | 0.026 * |
| Liver mets. (no vs. yes) | 1 (0.3–3.5) | 0.94 | 1.6 (0.47–5.8) | 0.40 |
| Pleural mets. (no vs. yes) | 0.5 (0.25–1.2) | 0.13 | 0.7 (0.36–1.6) | 0.51 |
| Supra-adrenal mets. (no vs. yes) | 1.8 (0.8–4.1) | 0.16 | 1.4 (0.6–1.4) | 0.42 |
| Baseline intact CTC (<5 vs. ≥5) | 2.4 (1–5.7) | 0.043 * | 3.1 (1.2–8.2) | 0.016 * |
| Baseline CK+ CD45+ (<2 vs. ≥2) | 0.6 (0.25–1.6) | 0.35 | 0.6 (0.3–1.5) | 0.31 |
| Baseline apoptotic CTC (<2 vs. ≥2) | 1.8 (1.2–5.5) | 0.025 * | 2.6 (1.2–8.3) | 0.009 * |
| Baseline CK+ fragments (<2 vs. ≥2) | 2 (1.3–4.4) | 0.036 * | 1.7 (0.8–3.9) | 0.15 |
| Baseline Blood cells (<17 vs. ≥17) | 0.8 (0.39–1.6) | 0.51 | 1.1 (0.5–2.4) | 0.78 |
| Baseline intact/apoptotic CTC (<2 vs. ≥2) | 1.9 (0.9–2.9) | 0.016 * | 2.3 (0.6–2.8) | 0.021 * |
| Baseline intact/apoptotic CTC+ CK+ fragments (<5 vs. ≥5) | 3.1 (1.5–6.8) | 0.003 * | 2.7 (1.1–6.6) | 0.025 * |
PFS: Progression Free Survival; OS: Overall Survival; HR: Hazard Ratio; CI: Confidence Interval; ECOG: Eastern Cooperative Oncology Group; PS: Performance Status. * p ≤ 0.05.